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A series of substituted 1,5-diarylpyrrole-3-alkoxyethyl ethers were previously synthesized and the po-
tential anti-inﬂammatory and antinociceptive activities of these compounds were evaluated in vivo. The
compounds displayed a very good activity against both carrageenan-induced hyperalgesia and oedema in
the rat paw test. Therefore, in a very preliminary test, compounds (8a,b) showed antiproliferative activity
in the HaCaT (aneuploid immortal keratinocyte from adult human skin) cell models. On these basis, our
research continued with the synthesis of ﬂuorinated derivatives (8c,d, 9b-d, and 10b-d) with the aim of
improving the pharmacokinetic proﬁle of the previous active compounds. Substitution of a hydrogen
atom by a ﬂuorine atom may change the conformational preferences of the molecules due to stereo-
electronic effects and also ﬂuorine atom may be able to exert the metabolic obstruction reducing the
“ﬁrst-pass effect”. Compound 10b exhibited a prominent in vivo anti-inﬂammatory and antinociceptive
activities, in addition its antiproliferative power in an in vitro model of human skin cancer is herein
described.
© 2015 Elsevier Masson SAS. All rights reserved.1. Introduction
Prostaglandin G/H synthase enzymes (PGHS), commonly known
as cyclooxygenases (COX), are responsible for the formation of
important biological mediators called prostanoids, which play a
critical role in various biological processes [1]. Arachidonic acid
(AA) is a 20 carbon unsaturated fatty acid distributed throughout
the lipid bilayer of the cell membranes. Phospholipase A2 (PLA2)i).
ery, Grifﬁth University, Bris-
served.enzymes cleave membrane bound arachidonate for the conversion
into bioactive precursors. AA can be metabolized through COX
pathway via a two-step process: the ﬁrst step involves conversion
of AA to prostaglandin G2 (PGG2), a 9,11-endoperoxide-15-
hydroperoxide, and in the second step peroxidase reduces PGG2
to prostaglandin H2 (PGH2). Speciﬁc PG synthases further metab-
olize PGH2 to give structurally related bioactive lipids, including
PGs PGE2, PGD2, PGF2a, prostacycline PGI2 and thromboxane A2
(TxA2) [2].
Non-Steroidal Anti-Inﬂammatory Drugs (NSAID), which include
both traditional NSAIDs (tNSAIDs) and selective inhibitors of COX-2
(COXib) (Fig. 1), relieve pain and inﬂammation suppressing the COX
function of PGHS and the consequent formation of PGE2 and
Fig. 1. Structures of reference compounds.
Fig. 2. Structure of ﬂuorinated compounds 8c,d, 9b-d and 10b-d.
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Long-term therapy with tNSAIDs generates adverse gastroin-
testinal complications ranging from stomach erosions and silent
intestinal ulcerations to life-threatening complications [3]. Selec-
tive inhibitors of COX-2 depress prostacyclin (PGI2), an atheropro-
tective agent, but not COX-1-derived thromboxane A2 (TXA2), a pro-
aggregatory and vasoconstrictor mediator, which might predispose
patients to heart attack and stroke [4]. In 2004, Rofecoxib, (4-[4-
(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone), marketed as
Vioxx was withdrawn from the market due to increased risk for
cardiovascular thrombotic events in a long term-therapy [5].
Moreover, the involvement of COX-2 in cancer development was
previously evidenced by pharmacological analysis of PGs in
different human cancers. PGE2 speciﬁcally exerts carcinogenic ef-
fects in the human body. It was found that premalignant lesions
and established cancers produce excessive quantities of PGE2 and
this enhances tumor cell growth and increases tumor invasiveness
[1]. COX-2 is up-regulated in a number of epithelial cancers,
including those originating in the colon and rectum, stomach,
breast, prostate, and lung [6]. In the context of cutaneous tissues,
increased expression of COX-2 and production of its primary
product PGE2 have been reported to increase cell growth and
decrease apoptosis. PGE2 is also thought to be responsible for
different skin cancers, such as squamous cell and basal cell carci-
noma [7].
During the last decade a large number of COX inhibitors have
been described. In particular, very recently novel chemical entities
have been identiﬁed by different approaches such as: i) rational
design providing novel scaffolds based on 4-phenylpyrimidine-
2(1H)-thiones [8] and, indole based peptidomimetics [9], or ii)
computational procedures providing novel and structurally unre-
lated COX-2 inhibitors [10].
Within a large programme devoted to the design and synthesis
of new anti-inﬂammatory agents based on a diaryl heterocyclic
scaffold, we previously synthesized different series of 1,5-
diarylpyrrole-3-acetic esters 7 [11] and 3-alkoxyethyl ethers 8a,b
[12] as new selective COX-2 inhibitors, in which the pyrroloaceticsubunit, reminiscent of indomethacine and clopirac was conju-
gated with vicinal diaryl moiety mimicking the main feature of
COXib (Fig. 1).
These compounds were shown to be potent and highly selective
COX-2 inhibitors in in vitro cell culture assays [12e14]. The potential
anti-inﬂammatory and antinociceptive activities of these com-
pounds were also evaluated in vivo, demonstrating a very good
activity against both carrageenan induced hyperalgesia and
oedema in rat paw test. Furthermore, compounds 8a,b showed, in a
very preliminary screening, a clear inhibition of cell proliferation on
HaCaT cells with non-toxic effects in the range between 10 and
100 mM [7].
Encouraged by these data, we focused our attention on the
preparation of two homologous series of differently ﬂuorinated 3-
substituted-1,5-diarylpyrrole alkoxyethyl ethers (8c,d; 9b-d and
10b-d) (Fig. 2) with the aim of investigating the biological effects
that can be elicited by the insertion of a ﬂuorine atom on different
portion of the previously synthesized COX-2 inhibitors. Compound
10b, which displays the best biological proﬁle in terms of afﬁnity
and selectivity toward COX-2, as well as percent inhibition of the
enzyme (cell culture assay), was also investigated for its in vivo
anti-inﬂammatory, analgesic and antiproliferative activity, dis-
playing interesting results.
2. Results and discussion
2.1. Chemistry
The synthetic procedure used to obtain ﬁnal compounds 8c,d,
9b-d and 10b-d is depicted in Scheme 1. Brieﬂy, the suitable alco-
hols 11c-d were treated with propyl iodide in NaOH 50% (w/w)
solution, following the previously reported procedure [12] to
obtain ﬁnal compounds 8c,d. Using the same procedure, derivatives
11b-d were treated with the proper hydroxyalkyl bromide in its
tetrahydropyranyl protected form [15] (see Supplementary Mate-
rial) to yield compounds 12b-d and 13b-d that were successively
deprotected to give hydroxyalkyl ethers 14b-d and 15b-d. These
derivatives were then activated by tosylation and treated with
Bu4NþF to afford ﬂuorinated compounds 9b-d and 10b-d in
satisfactory yield. Purity of compounds 8c,d, 9b-d, 10b-d was
assessed by RP-HPLC and was found to be higher than 95% (see
Supplementary Material for further details).
2.2. Structure-activity relationship, molecular modeling studies and
biological evaluation
In this limited series of compounds the presence of an additional
ﬂuorine atom in the 3-alkoxyalkyl side-chain with respect to
compounds 8a,b would allow us to assess if the contemporary
presence of ﬂuorine atoms in two different portions of themolecule
could inﬂuence the interaction of these new inhibitors with the
COX-2 active site. In particular, compounds 8c,d were synthesized
Scheme 1. Synthesis of compounds 8c,d, 9b-d, and 10b-d. Reagents and conditions:(i)
Propyl iodide, (Bu4Nþ)Br, Sodium hydroxide, 50% (w/w) aqueous solution, 60 C, 72 h;
(ii) Br(CH2)nOTHP, (Bu4Nþ)Br, Sodium hydroxide, 50% (w/w) aqueous solution, 60 C,
72 h (iii) PPTS, MeOH, 55 C, 20 h; (iv) DMAP, DIPEA, TsCl, DCM, r.t., 4 h; (v) (Bu4Nþ)
Fin THF, 1 M; dry THF, 80 C, 3 h.
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ﬂuoro substituent in the pendant N1 aromatic ring could lead to
biological results comparable with those previously reported for
compounds 8a and 8b [12].
The effects of a ﬂuorine atom as a substituent on physical and
chemical properties, as lipophilicity, electronic properties,
hydrogen bonding, and metabolic stability are well known [16,17].
The difference in electronegativity between carbon and ﬂuorine
generates a large dipole moment in this bond that, when combined
with the electrostatic distribution of a speciﬁc molecule, may
contribute to the molecule's ability to establish intermolecular
interactions.
By means of in vitro cell culture (J774 murine macrophage)
assay, the title compounds were evaluated for their inhibitory po-
tency and selectivity on both COX-isoforms and the results are
resumed in Table 1.
Results showed that in compounds 8c,d, the presence of a ﬂuoro
substituent in meta and in meta/para position of the pendant N1
ring did not alter the inhibitory potency and selectivity with respect
to previously reported analogues 8a,b. In compounds sharing
general structures 9 and 10, the replacement of a hydrogen atom
with ﬂuorine in the side chain coupled with the presence of mono-
or diﬂuoro-substitution on the N1 pendant ring led to contrasting
effects on the inhibitory activity of the resulting compounds.
Accordingly, for meta-substituted compounds 9c and 10c, a
considerable decrease of COX-2 inhibition was observed whereas
the para-ﬂuoro derivative 10b, showed a signiﬁcantly improved
inhibitory activity (IC50 ¼ 0.007 mM) when compared with that of1,5-diarylpyrrole-3-propoxyethyl-, 3-ﬂuoroethoxyethyl-, and 3-
ﬂuoropropoxyethyl ethers 8a-d, 9c,d, and 10c,d, respectively, the
IC50 of which ranges from 0.018 to 0.030 mM. The in vitro potency
and selectivity showed by compound 10b appears more striking
when compared to that of celecoxib (5) the IC50 of which being
0.079 mM (11-fold less potent and much more less selective than
10b).
Next, the new ﬂuorinated derivatives were analysed by means
of molecular docking calculations using Glide software (Glide
version 5.7, Schr€odinger, LLC, New York, NY, 2011), with the aim of
investigating the potential binding modes of such inhibitors within
the COX-2 binding site. The selected compounds 9b and 10b
differing for one carbon atom in the ﬂuorinated tail, showed a
similar binding mode to those found for a previously reported COX-
2 inhibitors [18]. In particular, compound 9b strongly interacts with
the COX-2 active site by a series of polar contacts with the backbone
of Phe518 and with the side-chain of Arg120. Moreover, one pep
stacking was established between Tyr355 and 9b (Fig. 3). The ﬂu-
orophenyl moiety interacts with a series of hydrophobic residues as
depicted in Fig. 3B. These interactions of 9b into COX-2 binding site
result in docking XPscore of 8.47 kcal/mol and in estimated free
binding energy (DGbind) of 97.74 kcal/mol.
As depicted in Fig. 4, compound 10b showed a similar binding
mode with respect to that found for 9b. In fact, 10b established the
same hydrophobic/polar contacts previously described. Also, the
docking score and the estimated free binding energy resulted
comparable to those calculated for 9b (XPscore 9.27 kcal/mol;
DGbind 100.97 kcal/mol). Remarkably, all the newly synthesized
compounds reported in Table 1 showed a comparable binding
mode as well as the docking score and the estimated DGbind (data
not shown), conﬁrming the strong afﬁnity of this kind of scaffold
for COX-2 enzyme.
On the basis of its very encouraging in vitro COX-2 inhibitory
activity, compound 10b was evaluated in a rat model of acute in-
ﬂammatory pain. As shown in Table 2, inﬂammatory pain was
induced by the intraplantar administration of carrageenan.
The anti-inﬂammatory effect of the new compounds emerged
also by the measurement of the paw edema volume, it was signif-
icantly decreased by 10b (3e20 mg kg1) (Table 2). To evaluate the
pain reliever proﬁle of the active compound 10b, its antinociceptive
efﬁcacy and potency was assessed in the model of visceral pain
induced by the intraperitoneal (i.p.) injection of a 0.6% acetic acid
solution (Writhing test). The abdominal contractions induced by
the acid solution (about 30 writhing in vehicle-treated animals,
Table 3), were dose-dependently prevented by the administration
p.o. of 10b. The measurement performed 30 min after 20 mg kg1
10b treatment showed a number of writhing reduced to 10.7 ± 2.5
(Table 3).
The efﬁcacy of compound 10b was also evaluated in the rat
osteoarthritis model induced by the intra-articular injection of
monoiodoacetate (MIA) (Table 4). The injection of MIA in the knee
joint induces necrosis of chondrocytes with decrease of cartilage
thickness and osteolysis [19]. Kobayashi et al. showed that MIA is
able to disorganize chondrocytes and to promote cartilage erosion
[20]. These alterations are comparable with joint damages typical
of humans affected by osteoarthritis [21e23]. Brieﬂy, on day 14
after MIA injection the pain threshold on the ipsilateral paw was
decreased to 39.2 ± 3.2 g in comparison to 62.9 ± 2.3 g of control
rats as evaluated by Paw pressure test. Compound administered
p.o. was able to reduce articular pain starting from the dosage of
3 mg kg1. Twenty mg kg1 of 10bwere effective up to 60 min after
treatment reaching the threshold of 54.5 ± 3.5 g (60 min, Table 4).
The repeated treatment with 10b signiﬁcantly prevented MIA
dependent hyperalgesia (before treatment). A further compound
administration (after treatment, 30 min) did not induce an additive
Table 1
In vitro inhibition (J774 murine macrophage assay) of COX-1 and COX-2 by compounds 8a-d, 9b-d, and 10b-d.
Cpd X Y n COX-1 IC50 (mM)a COX-2 IC50 (mM)a COX-1/COX-2 (SI)b
8ac H F e >100 0.018 >5555
8bc F F e >100 0.030 >3333
8c H F e >100 0.013 >7692
8d F F e >100 0.018 >5555
9b F H 2 >100 0.013 >7692
9c H F 2 >100 0.140 >714
9d F F 2 >100 0.029 >3448
10b F H 3 >100 0.007 >14,285
10c H F 3 >100 0.135 >2857
10d F F 3 >100 0.019 >5263
Celecoxibd 5.1 0.079 65
a Results are expressed as the mean (n ¼ 3) of the % inhibition of PGE2 production by the test compounds with respect to control sample and IC50 values were calculated by
GraphPad Instat program.
b IC50 (COX-1)/IC50 (COX-2).
c See Ref. [12].
d See Ref. [13].
Fig. 3. (A) Best docked pose for compound 9b (green sticks) into COX-2 (orange cartoon PDB ID: 6COX) binding site. The key residues in the active site were represented by lines. H-
bonds were represented by black dotted lines. The hydrogens were omitted for the sake of clarity. The picture was generated by means of PyMOL (The PyMOL Molecular Graphics
System, v1.6-alpha; Schrodinger, LLC, New York, 2013). (B) Ligand interaction diagram (Maestro version 9.3, Schr€odinger, LLC, New York, NY, 2012. (For interpretation of the ref-
erences to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. (A) Best docked pose for compound 10b (grey sticks) into COX-2 (orange cartoon PDB ID: 6COX) binding site. The key residues in the active site were represented by lines. H-
bonds were represented by black dotted lines. The hydrogens were omitted for the sake of clarity. (B) Ligand interaction diagram. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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with the present anti-inﬂammatory compounds could be able to
prevent the joint damage and, consequently, pain [21e24].
In addition to the canonical anti-inﬂammatory and anti-
nociceptive activities, many studies highlighted the potential of
COX-2 inhibitors in the prevention of several cancer types such ascolon, breast, lung and prostate cancers [25e28] most likely by
modulating the cell proliferation pathways. So, title compounds
were evaluated to assess their effects on cell toxicity by means of
LDH release assay and potential antiproliferative activity using
HaCaT, aneuploid immortal keratinocyte cell line from adult human
skin [7].
Table 2
Effect of 10b on carrageenan-induced acute inﬂammatory pain hypersensitivity (paw-pressure test) and paw edema.
Paw-pressure (g) Paw volume (mL)
Pre-treatment intraplantar Treatment per os Dose mg kg1 Before treatment After treatment
30 min 60 min 90 min 120 min 60 min
Vehicle Vehicle 57.6 ± 2.2 63.8 ± 2.9 59.4 ± 3.3 62.7 ± 2.8 64.6 ± 3.2 1.45 ± 0.08
Carrageenan Vehicle 33.9 ± 3.1 34.1 ± 2.3 35.4 ± 3.6 37.2 ± 3.4 34.5 ± 4.4 2.73 ± 0.07
Carrageenan 10b 3 30.5 ± 2.6 45.2 ± 4.6** 49.2 ± 3.7** 44.8 ± 3.0 36.2 ± 3.3 2.38 ± 0.06*
Carrageenan 10b 10 31.8 ± 2.7 51.7 ± 4.1** 53.5 ± 3.9** 47.2 ± 4.4** 38.1 ± 2.9 2.15 ± 0.08**
Carrageenan 10b 20 30.5 ± 2.0 53.9 ± 3.7** 56.3 ± 4.6** 44.9 ± 3.7** 35.5 ± 2.6 2.06 ± 0.05**
Carrageenan (Car, 1%, 100 mL) was injected in the left posterior sole 2 h before pain evaluation by the paw pressure test. Molecule or vehicle (1% carboxymethylcellulose) was
administered intraplantarly at time 0 and measures were performed at time 30, 60, 90 and 120 min. The volume of the paw edema was measured at time 60 min. Values are
the mean ± s.e.m. of 6 animals. *P < 0.05 and **P < 0.01 vs the carrageenan þ vehicle group.
Table 3
Effect of 10b in the mouse abdominal contraction test (acetic acid 0.6%).
Treatment per os Dose mg kg1 Number of writhes 30 min Number of writhes 60 min
Vehicle 30.5 ± 1.7 32.5 ± 2.4
10b 3 21.8 ± 2.5** 24.6 ± 2.7*
10 11.4 ± 3.1** 17.7 ± 3.1**
20 10.7 ± 2.5** 16.9 ± 2.7**
10bwas administered 30 or 60 min before the experiment. 0.6% acetic acid was administered intraperitoneally 5 min before the observation. Each value represents the mean
of 12 mice per group. *P < 0.05 and **P < 0.01 versus vehicle-treated mice.
Table 4
Effect of 10b on monoiodoacetate-induced osteoarthritis hypersensitivity in the rat paw-pressure test.
Pre-treatment intraplantar Treatment per os Dose mg kg1 Before treatment Paw-pressure (g)
After treatment
30 min 60 min 90 min 120 min
Vehicle Vehicle 62.9 ± 2.3 60.5 ± 2.4 58.3 ± 4.0 66.3 ± 4.1 61.5 ± 3.2
MIA Vehicle 39.2 ± 3.2 37.8 ± 3.3 36.1 ± 3.5 37.8 ± 3.1 39.2 ± 4.0
MIA 10b 3 36.5 ± 2.5 47.9 ± 4.2** 45.4 ± 3.8* 42.4 ± 3.5 39.0 ± 3.1
10 38.8 ± 2.8 50.3 ± 4.4** 51.8 ± 3.7** 44.3 ± 3.8 40.6 ± 3.5
20 37.8 ± 2.2 51.3 ± 3.3** 54.5 ± 3.5** 43.8 ± 3.1 37.1 ± 2.9
Effect of 10b on monoiodoacetate (MIA)-induced unilateral osteoarthritis. MIA (2 mg/25 mL) was injected in the left posterior tibiotarsal articulation 14 days before pain
evaluation by the paw pressure test. Molecules or vehicle were administered intraperitoneally at time 0 and measures were performed at time 30, 60, 90 and 120 min. Values
are the mean ± s.e.m. of 6 rats. *P < 0.05 and **P < 0.01 in comparison with MIA þ vehicle treated rats.
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proliferation
Cytotoxicity of compounds was evaluated in HaCaT cells after
treatment with doses ranging from 1 to 50 mM by means of LDH
release. As shown in Fig. 5, 24 h after treatment no cytotoxicity was
detected.Fig. 5. Cytotoxicity of compounds 8c,d, 9b-d, and 10b-d ranging from 1 to 50 mM after 24 h w
of Triton X-100 (100%) (averages of three different experiments, *p < 0.05).As shown in Fig. 6, the treatment with compounds 8c,d, 9b-d,
and 10b-d for 24 h, had a clear dose-dependent effect on cellular
proliferation as measured by 5-bromo-20-deoxyuridine (BrdU)
incorporation. Indeed, while 1 mM did modify cellular proliferation,
the treatment with higher albeit not toxic doses (10 and 50 mM)
evidenced a drastic and signiﬁcant cellular growth inhibition for
8d, 9b, 9c 9d, 10b and 10d compared to the control cells (DMSOas evaluated in HaCaT cell line by LDH release assay. Data are expressed as percentage
Fig. 6. The effect on cell proliferation of compounds 8c,d, 9b-d, and 10b-d on HaCaT cells was evaluated by means of BrdU incorporation after 24 h of treatment. Data are expressed
as percentage of control (averages of three different experiments, *p < 0.05).
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changes in BrdU incorporation. However, further investigation is
required to conﬁrm the antiproliferative activity showed by pre-
viously reported compounds 8a,b [7].
3. Conclusions
In this work, we have designed, synthesized and tested a new
series of ﬂuorinated 1,5-diarylpyrrole-3-alkoxyethyl ether de-
rivatives as COX-2 selective inhibitors. In vitro biological results are
in full agreement with all the previously published data, demon-
strating the high afﬁnity of the 1,5-diarylpyrrole scaffold for COX-2
active site. The afﬁnity was also conﬁrmed by molecular docking
calculations, proving that replacement of a hydrogen atom by
ﬂuorine in the alkyl side chain didn't modify steric and electronic
properties of the newly conceived chemical entities. Compound
10b demonstrated efﬁcacy in the model of rat acute inﬂammatory
pain and in the rat osteoarthritis model; thus, highlighting its
favourable potential to turn into a novel anti-inﬂammatory and
antinociceptive agents. Furthermore, the anti-proliferative but not
toxic effect of the most promising compounds in the presented
series on HaCaT cell suggests a possible application in the therapy
of human skin disorders.
4. Methods
4.1. Biological evaluation
4.1.1. In vitro inhibition of COX-1 and COX-2 enzymes
The in vitro COX-1 and COX-2 inhibition of compounds 8a-d, 9b-
d, and 10b-d was evaluated through cell-based assay employing
murine monocyte/macrophage J774 cell lines. The cell line was
grown in DMEM supplemented with 2 mM glutamine, 25 mM
HEPES, 100 units/mL penicillin, 100 mg/mL streptomycin, 10% fetal
bovine serum (FBS), and 1.2% sodium pyruvate. Cells were plated in
24-well culture plates at a density of 2.5 x 105 cells/mL and allowed
to adhere at 37 C in 5% CO2 for 2 h. Immediately before the ex-
periments, culture medium was replaced with fresh medium and
cells were stimulated as described previously [12]. The evaluation
of COX-1 inhibitory activity was achieved pre-treating cells with
test compounds (100 mM) for 15 min and then incubating them at
37 C for 30 min with 15 mM arachidonic acid to activate the
constitutive COX. At the end of the incubation, the supernatants
were collected for the measurement of PGE2 levels by a radioim-
munoassay (RIA). To evaluate COX-2 activity, cells were stimulated
for 24 h with Escherichia coli lipopolysaccharide (LPS, 10 mg/mL) toinduce COX-2, in the absence or presence of test compounds
(0.001e10 mM). The supernatants were collected for the measure-
ment of PGE2 bymeans of RIA. Celecoxibwas utilized as a reference
compound for the selectivity index. Triplicate wells were used for
the various conditions of the treatment in the cell culture assay
throughout the experiments. Results are expressed as the mean of
three experiments, of the % inhibition of PGE2 production by test
compounds with respect to control samples. Data ﬁt was obtained
using the sigmoidal dose-response equation (variable slope)
(GraphPad software). The IC50 values were calculated by the
GraphPad Instat program (GraphPad software).
4.1.2. Animals
For all the experiments described below, male CD1 albino mice
(23e25 g) or male SpragueeDawley rats (Harlan, Varese, Italy)
weighing approximately 200e250 g at the beginning of the
experimental procedure, were used. Animals were housed in CeSAL
(Centro Stabulazione Animali da Laboratorio, University of Flor-
ence) and used at least one week after their arrival. Four rats were
housed per cage (size 26  41 cm); animals were fed a standard
laboratory diet and tap water ad libitum, and kept at 23 ± 1 C with
a 12 h light/dark cycle, light at 7 a.m. All animalmanipulations were
carried out according to the European Community guidelines for
animal care (DL 116/92, application of the European Communities
Council Directive of 24 November 1986 (86/609/EEC). The ethical
policy of the University of Florence complies with the Guide for the
Care and Use of Laboratory Animals of the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996; University of
Florence assurance number: A5278-01). Formal approval to
conduct the experiments described was obtained from the Italian
Ministry of Health (N54/2014-B) and from the Animal Subjects
Review Board of the University of Florence. Experiments involving
animals have been reported according to ARRIVE guideline. All ef-
forts were made to minimize animal suffering and to reduce the
number of animals used.
4.1.3. Carrageenan-induced acute inﬂammatory pain
One hundred mL of carrageenan solution (SigmaeAldrich; 1% in
saline) was injected intraplantarly into the rat left hind paw. Two h
after carrageen injection, compounds were per os (p.o.) adminis-
tered and their anti-hypersensitive effect was measured over time
by the paw pressure test. Control rats received 100 mL of vehicle
(saline) solution intraplantarly and saline i.p..
4.1.4. Abdominal contraction pain
At predetermined time intervals (30 and 60) after drug
A. Di Capua et al. / European Journal of Medicinal Chemistry 109 (2016) 99e106 105administration, mice were injected intraperitoneally with a 0.6%
(w/w) solution of acetic acid (10 mL kg1), to induce pain sensation
evident from typical abdominal contractions of animals named
‘writhing’. The number of induced writhings was counted for
10 min, starting 5 min after acetic acid injection [29].
4.1.5. Monoiodoacetate-induced osteoarthritis
Unilateral osteoarthritis was also induced by injection of mon-
oiodoacetate (MIA, SigmaeAldrich) into the rat tibio-tarsal joint
[30]. On day 0, rats were slightly anesthetized by 2% isoﬂurane, the
left leg skin was sterilized with 75% ethyl alcohol and the lateral
malleolus located by palpation; then, a 28-gauge needle was
inserted vertically to penetrate the skin and turned distally for
insertion into the articular cavity at the gap between the tibio-
ﬁbular and tarsal bone until a distinct loss of resistance was felt.
2mgMIA in 25 mL salinewere delivered into the left articular cavity.
The paw pressure was performed at day 14. The tested compounds
were p.o. administered. Control rats received 25 mL of saline solu-
tion (day 0) in the tibiotarsal joint and saline i.p. at day 14.
4.1.6. Paw pressure test
The pain threshold in the rat was determined with an anal-
gesimeter (Ugo Basile, Varese, Italy) as described [31]. Brieﬂy, a
constantly increasing pressure was applied to a small area of the
dorsal surface of the paw using a blunt conical probe. Pressure was
increased until a vocalization or a withdrawal reﬂex occurred. The
withdrawal threshold was expressed in grams, the test was
repeated twice and the mean was considered as the value for each
paw.
4.1.7. Edema volume measurement
Rat paw volumes were measured using a plethysmometer. Sixty
min after the injection of carrageenan, the paw volume of the
ipsilateral hind paw was measured and compared with
carrageenan þ vehicle-treated controls. The results are reported as
paw volume expressed in mL.
4.1.8. Statistical analysis of behavioral measurements
Results were expressed as means ± s.e.m. and the analysis of
variance was performed by one way ANOVA. A Bonferroni's sig-
niﬁcant difference procedure was used as post-hoc comparison. P
values of less than 0.05 or 0.01 were considered signiﬁcant. Data
were analyzed by means of the “Origin 9” software (OriginLab,
Northampton, USA).
4.1.9. Cell culture and treatments
HaCaT cells, (a cell line gift from Dr. F. Virgili), were grown in
Dulbecco's modiﬁed Eagle's medium High Glucose (Lonza, Milan,
Italy), supplemented with 10% FBS, 100 U/ml penicillin, 100 lg/ml
streptomycin and 2 mM L-glutamine as previously described [32].
Cell suspension containing 10 or 1105 viable cells/ml were used.
Cells were incubated at 37 C for 24 h in 95% air/5% CO2 until 80%
conﬂuency. HaCaT cells were treated with different doses of title
compounds at different time points (30 min, 1, 3 and 24 h). After
treatment, cells or medium were collected for the several assays
described below. Compounds were dissolved in DMSO at a con-
centration of 10 mM as a stock solution. The stock was diluted to
the required concentrations directly in the medium. The ﬁnal
concentration of DMSO in culture medium during compounds
treatment did not exceed 0.1% (v/v).
4.2. Computational details
All calculations performed in this work were carried out on
Cooler Master Centurion 5 (Intel Core-i5 Quad CPU Q6600 @2.40 GHz) with Ubuntu 10.04 LTS (long-term support) operating
system running Maestro 9.2 and Maestro 9.3 (Schr€odinger, LLC,
New York, NY, 2011 and Maestro version 9.3, Schr€odinger, LLC, New
York, NY, 2012, respectively).
4.2.1. Molecular docking studies
4.2.1.1. Molecules preparation. Three-dimensional structures of
compounds were built by means of Maestro (Maestro version 9.2,
Schr€odinger, LLC, New York, NY, 2011). Molecular energy minimi-
zations were performed by means of MacroModel using the Opti-
mized Potentials for Liquid Simulations-all atom (OPLS-AA) force
ﬁeld 2005 [33,34]. The solvent effects are simulated using the
analytical Generalized-Born/Surface-Area (GB/SA) model [35], and
no cutoff for nonbonded interactions was selected. Polak-Ribiere
conjugate gradient (PRCG) method with 1000 maximum itera-
tions and 0.001 gradient convergence threshold was employed. The
compounds were treated by LigPrep application (LigPrep version
9.2, Schr€odinger, LLC, New York, NY, 2011), implemented inMaestro
suite 2011, generating the most probable ionization state of any
possible enantiomers and tautomers at cellular pH value (7 ± 0.5).
4.2.1.2. Protein preparation. The three-dimensional structure of
COX-2 was taken from PDB (PDB ID: 6COX) and imported into
Schr€odinger Maestro molecular modeling environment. The
structure was submitted to protein preparation wizard imple-
mented in Maestro suite 2011 (Protein Preparation Wizard work-
ﬂow 2011) as previously reported [36,37]. This protocol through a
series of computational steps, allowed us to obtain a reasonable
starting structure of the proteins for molecular docking calculations
by a series of computational steps. In particular, we performed
diverse steps to (1) add missing residues or side-chains, (2) add
hydrogens, (3) optimize the orientation of hydroxyl groups, Asn,
and Gln, and the protonation state of His, and (4) perform a con-
strained reﬁnement with the impref utility, setting the max RMSD
of 0.30. The impref utility consists of a cycles of energy minimiza-
tion based on the impact molecular mechanics engine and on the
OPLS_2005 force ﬁeld [33,34].
4.2.1.3. Molecular docking. Docking studies were carried out by
Glide (Grid-Based Ligand Docking with Energetics) using the li-
gands and the protein prepared as above-mentioned, applying
Glide extra precision (XP) method [38,39]. Energy grid was pre-
pared using default value of protein atom scaling factor (1.0 Å)
within a cubic box centered on the crystallized inhibitor. After grid
generation, the ligands and the crystallized inhibitor were docked
into the enzymes with default parameters (no constraints were
added). The number of poses entered to post-dockingminimization
was set to 50. Glide XP score was evaluated. The XP method
correctly accommodated the crystallized inhibitors into the binding
site (data not shown).
4.2.1.4. Estimated free binding energy. The Prime/MM-GBSA
method implemented in Prime software (Prime version 3.0,
Schr€odinger, LLC, New York, NY, 2011) consists in computing the
change between the free and the complex state of both the ligand
and the protein after energy minimization. The technique was used
on the docking complexes of the selected compounds presented in
this study. The software was employed to calculate the free-binding
energy (DGbind) as previously reported by some of us [40e42].
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